Dr. Roman Perez-Soler – Mesothelioma Doctor – Associate Director of Clinical Oncology

Share This:

New York University Medical Center

Kaplan Cancer Center

550 First Avenue

New York, New York 10016

Phone: 212.263.8043

Email Address: roman.rerezso@nyu.edu

Dr. Roman Perez-Soler is Associate Director of Clinical Oncology at the New York University Medical Center, Kaplan Cancer Center. Dr. Perez-Soler is also listed as Chairman of the Department of Oncology at Montefiore Medical Center; Director of the Division of Medical Oncology at Albert Einstein College of Medicine; Associate Director for Clinical Research at Albert Einstein Cancer Center, and Professor of Medicine and Molecular Pharmacology at the Albert Einstein College of Medicine. The contact information for Dr. Roman Perez-Soler at Montefiore Medical Center is: 111 East 210th Street , Hofheimer Main, Room 100, Bronx , NY 10467, 718.920.4001. Dr. Perez-Soler is also a Scientific Advisor to Easton Capital Investment Group with offices in New York, New York, Buffalo, New York, and Miami, Florida.

Dr. Perez-Soler specializes in medical oncology. He is the principal investigator of the Phase II L-NDDP/Platar trial for pleural mesothelioma. He has received multiple awards for his accomplishments in lung cancer research, and he is also considered an international cancer expert in experimental cancer therapy.

Dr. Perez-Soler received his Medical Degree (M.D.) from Universidad Autonoma in Barcelona, Spain, in 1977. He completed his Residency in Internal Medicine at Universidad Autonoma from 1979-1982. From 1982-1985, Dr. Perez-Soler completed his Fellowship in Medical Oncology at the M.D. Anderson Cancer Center in Houston, Texas. Dr. Perez received his Board Certification in Internal Medicine in 1987 and 1989, and his Board Certification in Medical Oncology in 1989.

Dr. Perez-Soler is a member of the Executive Advisory Committee of the General Clinical Research Center (GCRC). In addition to memberships and numerous awards for his accomplishments in lung cancer research, Dr. Perez-Soler also has more than 100 articles, papers, and studies to his credit. The following titles represents only a small portion of Dr. Perez-Soler’s publishing credits.

Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer; The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma; Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer; Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression; Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis; Novel agents in the treatment of lung cancer: conference summary statement, and Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?